Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAthanassiades, A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorBacoyiannis, C.en
dc.contributor.authorBriassoulis, E.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:00:08Z
dc.date.available2015-11-24T19:00:08Z
dc.identifier.issn0093-7754-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19486
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAlopecia/chemically induceden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/toxicityen
dc.subjectDeoxycytidine/administration & dosage/analogs & derivativesen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHead and Neck Neoplasms/*drug therapyen
dc.subjectHumansen
dc.subjectImmunosuppressionen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Recurrence, Localen
dc.subjectPaclitaxel/administration & dosage/toxicityen
dc.titlePaclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck canceren
heal.abstractWe performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent or metastatic head and neck cancer. From March 1994 until August 1996, 49 patients were treated with paclitaxel 200 mg/m2 by 3-hour infusion followed by carboplatin at an area under the concentration-time curve of 7 mg/mL x min; treatment was requested every 4 weeks. Granulocyte colony-stimulating factor was administered prophylactically on days 2 to 12 of each cycle. The study included 41 men and eight women, with a median age of 57 years (range, 23 to 73 years). Most of the patients were symptomatic and had locoregional disease. Primary sites included nasopharynx (14 patients), oropharynx (six), oral cavity (four), hypopharynx (three), larynx (20), paranasal sinuses (one), and unknown (one). After the completion of treatment, four patients (8%; 95% confidence interval, 0% to 16%) achieved a complete response and 12 (24%; 95% confidence interval, 12% to 37%) achieved a partial response. Grade 3/4 toxicities included anemia (2%) and leukopenia, thrombocytopenia, nausea/vomiting, diarrhea, and stomatitis (4% each). After a median follow-up of 15.3 months, median time to progression was 5.7 months (range, 0.5 to 29.8+ months) and median survival was 13.3 months (range, 0.5 to 30.2+ months). In our ongoing study in a similar patient population, gemcitabine was substituted for carboplatin.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9427262-
heal.journalNameSemin Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ